With regards to mutational status, the V617F JAK2, CALR, and MPL mutations (driver mutations) are harbored by the pathological-cell population in 50–60%, 15–30%, and 1–5% of the ET cases, respectively. The gene discussed is JAK2; the disease is essential thrombocythemia.